Details for New Drug Application (NDA): 020596
✉ Email this page to a colleague
The generic ingredient in EPIVIR is lamivudine. There are twenty-nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the lamivudine profile page.
Summary for 020596
Tradename: | EPIVIR |
Applicant: | Viiv Hlthcare |
Ingredient: | lamivudine |
Patents: | 0 |
Pharmacology for NDA: 020596
Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Medical Subject Heading (MeSH) Categories for 020596
Suppliers and Packaging for NDA: 020596
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
EPIVIR | lamivudine | SOLUTION;ORAL | 020596 | NDA | ViiV Healthcare Company | 49702-205 | 49702-205-48 | 240 mL in 1 BOTTLE (49702-205-48) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 10MG/ML | ||||
Approval Date: | Nov 17, 1995 | TE: | AA | RLD: | Yes |
Expired US Patents for NDA 020596
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | EPIVIR | lamivudine | SOLUTION;ORAL | 020596-001 | Nov 17, 1995 | 7,119,202*PED | ⤷ Subscribe |
Viiv Hlthcare | EPIVIR | lamivudine | SOLUTION;ORAL | 020596-001 | Nov 17, 1995 | 5,047,407*PED | ⤷ Subscribe |
Viiv Hlthcare | EPIVIR | lamivudine | SOLUTION;ORAL | 020596-001 | Nov 17, 1995 | 6,180,639*PED | ⤷ Subscribe |
Viiv Hlthcare | EPIVIR | lamivudine | SOLUTION;ORAL | 020596-001 | Nov 17, 1995 | 6,004,968*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription